Loading provider…
Loading provider…
Hematology & Oncology Physician in Springfield, MO
NPI: 1174667109Primary Practice Location
MERCY HOSPITAL SPRINGFIELD
1235 E Cherokee St, Springfield, MO
Primary Employer
Mercy Clinic Springfield Communities
mercy.net
HQ Phone
Get MD Mohan's Phone Numberphone_androidMobile
Get MD Mohan's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardMO State Medical License

American Board of Internal Medicine
Hematology

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Medical Oncology
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 36415Insertion of needle into vein for collection of blood sample | 231 | 887 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 226 | 626 |
| 3 | 85025Complete blood cell count (red cells, white blood cell, platelets), automated test | 169 | 718 |
| 4 | 80053Blood test, comprehensive group of blood chemicals | 165 | 666 |
| 5 | 99215Established patient office or other outpatient, visit typically 40 minutes | 115 | 319 |
Authors: Jessica Clement, Jianjun Gao, Aria Jamshidi, Donald Richards, Allen Cohn
Journal: Ann Oncol
Publication Date: 2021-06-24
Lead Sponsor: ImmunityBio, Inc.
Intervention / Treatment: DRUG: N-803 + Pembrolizumab, DRUG: N-803 + Nivolumab, DRUG: N-803 + Atezolizumab, DRUG: N-803 + Avelumab, DRUG: N-803 + Durvalumab, DRUG: N-803 + Pembrolizumab + PD-L1 t-haNK, DRUG: N-803 + Nivolumab + PD-L1 t-haNK, DRUG: N-803 + Atezolizumab + PD-L1 t-haNK, DRUG: N-803 + Avelumab + PD-L1 t-haNK, DRUG: N-803 + Durvalumab + PD-L1 t-haNK, DRUG: N-803 + Docetaxel + Pembrolizumab, DRUG: N-803 + Docetaxel + Nivolumab
Lead Sponsor: Novartis Pharmaceuticals
Intervention / Treatment: DRUG: Placebo, DRUG: Canakinumab
Lead Sponsor: GRAIL, Inc.